Sherleen Chen, MD
Ophthalmology · Boston, MANPI 1528059383
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Alcon Research LLC at 47.8% of the total. Reporting peaked in 2020 at $1,750 and has fallen 86.4% since, to $238 in 2025.
Across 12 payments — averaging $304.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$2K
- Alcon$1K
- Dompe US, Inc.$120
- Apellis Pharmaceuticals, Inc.$118
- Sun Pharmaceutical Industries Inc.$114
- Johnson & Johnson Surgical Vision, Inc.$101
What the payments were for
- Consulting fees$1,75048%
- Travel & lodging$1,04829%
- Food & beverage$86224%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 1 | $1,750 |
| Alcon | 7 | $1,457 |
| Dompe US, Inc. | 1 | $120 |
| Apellis Pharmaceuticals, Inc. | 1 | $118 |
| Sun Pharmaceutical Industries Inc. | 1 | $114 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $101 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AcrySof IQ VIVITY IOL$1,750
- Oxervate$120
- Syfovre$118
- CEQUA$114
- VERITAS Vision System$101
How this compares
$3,660 in reported general payments places this provider in the 75th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 34 | $36,277 |
| Bromfenac Sodium | 96 | $19,010 |
| Prednisolone Acetate | 300 | $14,722 |
| LumiganBimatoprost | 20 | $14,505 |
| Cyclosporine | 30 | $10,317 |
| Timolol Maleate | 104 | $10,118 |
| ProlensaBromfenac Sodium | 21 | $6,887 |
| MoxifloxacinMoxifloxacin Hcl | 211 | $4,628 |
| Latanoprost | 316 | $3,759 |
| Ketorolac Tromethamine | 97 | $3,131 |
| Brimonidine Tartrate | 21 | $1,285 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 37 | $564 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 28 | $346 |
| Dorzolamide Hcl | 11 | $293 |
| ErythromycinErythromycin Base | 19 | $151 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Boston
- Rishi SinghBoston$1.7M
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Dean EliottBoston$250K
- Mina FarahaniBoston$227K
- Jia YinBoston$173K
- John MillerBoston$106K
- Elizabeth RossinBoston$101K
- Suzanne FreitagBoston$96K
- Nimesh PatelBoston$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.